Rafarma Establishes Advisory Board, Appoints First Member and Will Acquire Additional Patents and Intellectual Property

Ljubljana, Slovenia, April 06, 2020 (GLOBE NEWSWIRE) -- RAFARMA PHARMACEUTICALS INC. “OTC:(RAFA)” - In establishing its Advisory Board, Rafarma Pharmaceuticals announces the appointment of its first board member, Vladislav N. Laskavy, PhD., who will begin advising the company and assisting with the development of multiple treatment options as the company rolls out detox spas throughout Thailand and Europe. Dr. Laskavy is a well-known research scientist and has worked on numerous research projects studying Cancer, Autoimmune Deficiency, Viral Diseases, AIDS and many other diseases and treatments. Rafarma will also enter into non-dilutive agreements with Dr. Laskavy to acquire all of his intellectual property and patents, including multiple United States, Australian and other International patents which include patents for cancer treatment and stem cell therapy.

The addition of Dr. Laskavy enables Rafarma to add multiple treatment options to the company’s current Medicinal Marijuana treatment protocols. Rafarma CEO Vladimir Dolgolenko stated: “We feel the addition of Dr. Vladislav Laskavy to our advisory board will assist us in providing truly unique treatment options at our cutting-edge detox spas. We have an aggressive growth plan to implement our detox spas all throughout Thailand and Europe. With the current research from our Thailand partners and the new addition of Dr. Laskavy, we feel we will be able to provide an amazing health experience to our customers and patients”.

One of the new products Rafarma plans to roll out in its spas will be XR. XR belongs to a new class of immunomodulating drugs that contribute to the activation of an antigen-specific immune response, the development of which eliminates the infectious agent. More details and specifications for use of this drug will be released as the company moves forward. Rafarma is also excited to implement its own stem cell activation therapy using Dr. Laskavy’s patented techniques throughout the spas. All of the acquisitions will take place under agreements that will not cause dilution to the current holdings of the existing shareholders of Rafarma.

Dr. Laskavy stated: “I am very excited to be a part of the Rafarma Pharmaceuticals team and I look forward to the progress we can make treating those in need of help”. Rafarma expects the addition of Dr. Laskavy and his expertise to greatly enhance its current medical marijuana treatment offerings as well as other ground-breaking treatments to help people live healthier and stronger lives.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:

RAFARMA

(307) 429-2029